For the year ending 2025-10-31, PBSV had -$3,388,144 decrease in cash & cash equivalents over the period. -$221,530 in free cash flow.
| Cash Flow | 2025-10-31 |
|---|---|
| Net loss | 100,463 |
| Stock-based compensation | 35,079 |
| Depreciation and amortization | 59,866 |
| Amortization of operating lease right-of-use | 169,209 |
| Reinvested interests | 37,526 |
| Decrease in accounts receivable | -203,643 |
| Decrease (increase) in prepaids and other assets | -308,312 |
| Decrease in liabilities | -853,006 |
| Net cash used in operating activities | -214,886 |
| Acquisition of property. equipment and software | 6,644 |
| Marketable securities investment, net | -1,459,747 |
| Net cash used in investing activities | -1,466,391 |
| Repurchase of common stock | 31,443 |
| Cash dividends paid to shareholders | 1,719,918 |
| Net cash used in financing activities | -1,751,361 |
| Effect of exchange rate changes on cash | 44,494 |
| Net decrease in cash and cash equivalents | -3,388,144 |
| Cash and cash equivalents at beginning of period | 6,767,356 |
| Cash and cash equivalents at end of period | 3,379,212 |
Pharma-Bio Serv, Inc. (PBSV)
Pharma-Bio Serv, Inc. (PBSV)